HCM vs ZLAB: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. HCM and ZLAB share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined HCM and ZLAB exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

HUTCHMED (China) Limited trades on Nasdaq as ADSs under HCM, on the Hong Kong Stock Exchange as stock code 13, and on London's AIM market. It discovers and develops targeted oncology and immunology therapies in China and increasingly commercializes them globally through partners. Its marketed portfolio includes fruquintinib (sold as ELUNATE in China with Eli Lilly and as FRUZAQLA outside China with Takeda), surufatinib (SULANDA) for neuroendocrine tumors, and savolitinib (ORPATHYS) partnered with AstraZeneca. A separate Other Ventures segment, mainly prescription drug distribution in China, contributed ~$116 million of revenue in the first half of 2026 and is a lower-margin, non-innovative business that inflates headline revenue relative to the drug franchise.

Full HCM guide

Zai Lab was built on a specific arbitrage: find drugs that already work, license the Greater China rights before or during late-stage development, run the local trials and regulatory process, and sell them through a domestic commercial organization that Western partners do not want to build. That produced a portfolio of marketed products including ZEJULA (niraparib, a PARP inhibitor for ovarian cancer), the VYVGART franchise (efgartigimod, partnered with argenx, for generalized myasthenia gravis), XACDURO (sulbactam-durlobactam for Acinetobacter infections) and NUZYRA (omadacycline), with newer approvals for AUGTYRO, TIVDAK and KarXT rolling into launch through 2026. Total revenue was about $460 million in 2025 and roughly $450 million over the trailing twelve months, and management has described the China commercial business as profitable on its own before corporate R&D.

Full ZLAB guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• HCM drivers: ATTC platform licensing as the value unlock; China commercial rebound and fruquintinib's geographic spread.
• ZLAB drivers: Zoci as the first globally owned asset; Newly approved products entering commercial ramp.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Most of HUTCHMED's product economics run through partners, so Takeda, Eli Lilly and AstraZeneca decisions on pricing, launch pace and promotion shape results more than HUTCHMED's own execution does. For ZLAB, zai Lab's revenue is concentrated in mainland China and is therefore exposed to administered pricing rather than market pricing: national reimbursement drug list renewals cut prices as a condition of volume, and volume-based procurement of generics can collapse a branded franchise quickly, which is what happened to ZEJULA when generic olaparib entered.

Pick HCM if you believe its drivers more; ZLAB if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the HCM and ZLAB guides.

HCM. The headline revenue number is misleading on its own because ~$116 million of first-half 2026 revenue came from the low-margin Other Ventures drug distribution segment rather than innovative medicines; the oncology and immunology franchise generated ~$162.3 million, of which ~$40.9 million was milestone, royalty and R&D service income including an ~$18.1 million payment from Eli Lilly. Profitability is genuine but slim, with R&D of ~$78.8 million in the half consuming most of the gross profit. Because net cash covers roughly half the market value, valuation multiples on the operating business look far lower than a screener showing price-to-sales on the consolidated figure would suggest.

ZLAB. There is no earnings multiple to quote because Zai Lab does not earn anything yet, so the stock is valued on revenue, cash and pipeline probability instead. Backing out roughly $717 million of cash leaves about $1.6 billion of enterprise value against $450 million of trailing revenue, which is a low multiple for a specialty pharma commercial base and implies the market assigns close to nothing for the wholly owned oncology pipeline. Bulls point at that gap, bears point at a revenue line that shrank year over year in both Q1 and Q2 2026 while operating expenses stayed above $130 million a quarter.

Headline figures (approximate, September 2026): HCM shows market capitalization ~$2.4B (ADS ~$14, ~173M ADSs, each ADS = 5 ordinary shares), revenue (ttm) ~$549M (FY2025 ~$548.5M; H1 2026 ~$278.3M vs ~$277.7M in H1 2025), net income attributable (ttm) ~$18M (H1 2026 ~$15.9M; the ~$455M H1 2025 figure was mostly a one-off SHPL divestment gain), cash and short-term investments ~$1.37B at June 30, 2026, against ~$95M of bank borrowings; ZLAB shows revenue (ttm) ~$450 million, up ~5% year over year, q2 2026 revenue ~$106.3 million, down ~3% year over year but up ~11% sequentially on product sales, net loss ~$50.8 million in Q2 2026, ~$188 million over the trailing twelve months, cash and investments ~$717.5 million as of June 30, 2026.

HCM and ZLAB are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined HCM and ZLAB exposure against your real portfolio. It is not an investment adviser.